My research and clinical interests focus on improving outcomes in patients with lymphomas. I am interested in the use of novel agents and cellular therapies. I also have been involved in research activities using molecular imaging to predict response to therapy. During my fellowship, I published work that helped to define the role of PET scans in patients undergoing autologous stem cell transplant (ASCT) for relapsed lymphoma. It showed that residual activity on pre-ASCT PET scan is associated with poor outcomes after ASCT. I later designed the first clinical trial based on these findings using lenalidomide maintenance after ASCT for patients with relapsed lymphomas who had residual PET positive disease prior ASCT. The phase I portion of the trial has successfully completed and currently phase II continues to actively enroll patients. My other active investigator initiated trial is using a combination of a novel antibody based agent brentuximab with traditional chemotherapy for patients with CD30+ B-cell lymphomas. It is now being opened at two other institutions and I am serving as multi-site PI. I also actively participate in trials using cellular therapies (CART19) in patients with non-Hodgkin lymphomas. In the future, I would like to concentrate mainly on Hodgkin lymphoma since I am fascinated by the immunology of this disease and there is a great need to develop less toxic therapies for this lymphoma subtype affecting mostly young adults. I am working on establishing a comprehensive program for patients with Hodgkin lymphoma at the Abramson Cancer Center at the University of Pennsylvania. I am also the principal investigator on the first trial using cellular therapy with CART19 cells in Hodgkin lymphoma. I am hoping to expand this novel approach for Hodgkin lymphoma patients with relapsed/refractory disease and further develop immune based therapies in this setting.
Ruan, J., Martin, P., Shah, B., Schuster, S.J., Smith, S.M., Furman, R.R., Christos, P., Rodriguez, A., Svoboda, J., Lewis, J., Katz, O., Coleman, M., and Leonard, J.P.: Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell
New England Journal of Medicine 373(19): 1835-44, Nov 5 2015.
Marlise R. Luskin, Alex Ganetsky, Daniel Landsburg, Alison W. Loren, David Porter, Sunita Nasta, Jakub Svoboda, Selina Luger, Noelle Frey.: Nelarabine, cyclosphosphamide, and etoposide (NCE) for adults with relapsed T acute lymphoblastic leukemia and lymphoma. British Journal of Haematology 25, Sept 2015 Notes: Accepted for publication 8/13/2015. doi: 10.1111/bjh.13771.
Shah Nirav N, Kucharczuk Colleen R, Mitra Nandita, Hirsh Rebecca, Svoboda Jakub, Porter David, Loren Alison, Frey Noelle, Schapira Marilyn M: Implementation of an Advanced Practice Provider Service on an Allogeneic Stem Cell Transplant Unit: Impact on Patient Outcomes. Biology of Blood and Marrow Transplantation 21(9): 1692-8, Sept 2015.
Howlett Christina, Snedecor Sonya J, Landsburg Daniel J, Svoboda Jakub, Chong Elise A, Schuster Stephen J, Nasta Sunita Dwivedy, Feldman Tatyana, Rago Allison, Walsh Kristy M, Weber Scott, Goy Andre, Mato Anthony: Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. British Journal of Haematology 170(4): 504-14, Aug 2015.
Mato Anthony R, Foon Kenneth A, Feldman Tatyana, Schuster Stephen J, Svoboda Jakub, Chow Kar Fai, Valentinetti Marisa, Mrkulic Mary, Azzollini Kelly, Gadaleta Gabriella, Bhattacharyya Pritish K, Zenreich Joshua, Pascual Lauren-Nicole, Yannotti Kara, Kdiry Sabrina, Howlett Christina, Strelec Lauren, Porter David, Bejot Coleen, Goy André: Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia. American Journal of Hematology 90(6): 487-92, Jun 2015.
Huntington Scott F, Svoboda Jakub, Doshi Jalpa A: Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission. Journal of Clinical Oncology 33(13): 1467-74, May 2015.
Chong Elise A, Ahmadi Tahamtan, Aqui Nicole, Svoboda Jakub, Nasta Sunita D, Mato Anthony R, Walsh Kristy M, Schuster Stephen J: Combination of lenalidomide and rituximab overcomes rituximab-resistance in patients with indolent B-cell and mantle cell lymphomas. Clinical Cancer Research 21(8): 1835-42, Apr 15 2015.
Huntington Scott F, Nasta Sunita D, Schuster Stephen J, Doshi Jalpa A, Svoboda Jakub: Utility of interim and end-of-treatment FDG-PET/CT in frontline therapy of patients with diffuse large B-cell lymphoma. Leukemia & Lymphoma Page: 1-6, Feb 2015 Notes: [Epub ahead of print]
Shah Nirav N, Harrison Neil, Stonecypher Mark, Frank Dale, Amorosa Valerianna, Svoboda Jakub: Extracavitary primary effusion lymphoma initially presenting with hemophagocytic lymphohistocytosis. Clinical lymphoma, myeloma & leukemia 14(5): e157-60, Oct 2014.
Nagle Sarah J, Chong Elise A, Chekol Seble, Shah Nirav N, Nasta Sunita D, Glatstein Eli, Plastaras John P, Torigian Drew A, Schuster Stephen J, Svoboda Jakub: The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma. Cancer Medicine 4(1): 7-15, Sep 2014.
back to top
Last updated: 07/14/2016
The Trustees of the University of Pennsylvania